2003
DOI: 10.1179/joc.2003.15.1.85
|View full text |Cite
|
Sign up to set email alerts
|

Severe and Prolonged Hypoglycemia Triggered by Long-Acting Octreotide in a Patient with Malignant Mesenchymal Tumor: Case Report

Abstract: Somatostatin analogues are potent growth hormone and glucagon inhibitors and are commonly used in the treatment of several endocrine and non-endocrine disorders. We report severe and longstanding hypoglycemia triggered by long-acting octreotide (Sandostatin LAR) in a 62-year-old women with malignant mesenchymal tumor. Hypoglycemia developed after 6 hours of octreotide injection and she was admitted to the emergency unit with sweating, tremor, palpitation and confusion. On admission, her plasma glucose level wa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2005
2005
2016
2016

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…6,24 Long-acting octreotide has been associated with prolonged severe hypoglycemia in a patient with a malignant mesenchymal tumor, possibly as a result of a reduction in glucagon levels and other counterregulatory hormones. 25 In 2 of our cases, a somatostatin analog was a useful adjunctive therapy when added to glucocorticoids. If a somatostatin analog is considered as a treatment of NICTH, a therapeutic trial with short-acting octreotide under close supervision is advisable to test for paradoxic worsening of symptoms.…”
Section: Discussionmentioning
confidence: 94%
“…6,24 Long-acting octreotide has been associated with prolonged severe hypoglycemia in a patient with a malignant mesenchymal tumor, possibly as a result of a reduction in glucagon levels and other counterregulatory hormones. 25 In 2 of our cases, a somatostatin analog was a useful adjunctive therapy when added to glucocorticoids. If a somatostatin analog is considered as a treatment of NICTH, a therapeutic trial with short-acting octreotide under close supervision is advisable to test for paradoxic worsening of symptoms.…”
Section: Discussionmentioning
confidence: 94%